News

Early Parkinson’s patients with rapid eye movement sleep behavior disorder (RBD) have more severe symptoms and show a faster disease progression in terms of motor, mood, and cognitive symptoms, according to a U.K. study. Moreover, these patients had a higher risk of frequent falls, freezing of gait — when…

Top-line results are expected to be released by the end of this year for Pharma Two B’s multinational trial investigating the safety and efficacy of P2B001 for treating early stage Parkinson’s disease. Pharma Two B announced that its researchers have finished treating patients in the Phase 3 trial, which…

Several new clinical trial data analyses support the benefits and superiority of Gocovri (amantadine) over other therapies in lessening off episodes — periods when levodopa treatments stop working and motor symptoms return — and involuntary movements called dyskinesia in people with Parkinson’s disease. These analyses compared Gocovri, marketed by…

Using a novel approach, called Placebell, could help researchers in clinical trials to understand the placebo effect in people with Parkinson’s disease, and boost the strength of their findings. Researchers at Tools4Patient, which is developing Placebell, and other institutions presented data on the approach at the…

Studies on twins and families have suggested that susceptibility to Parkinson’s disease has a substantial genetic component. Now, an analysis of gene activity in different brain tissues has identified gene candidates that may be directly involved in causing the neurodegenerative disorder. The study, “A transcriptome-wide association study…

The Parkinson’s Foundation is launching a four-year, $30-million fundraising campaign to help advance Parkinson’s research and fund community services. The Reach Further campaign seeks to help accelerate research, increase patient access to healthcare, and enrich community services for those affected by Parkinson’s disease. “With the rate of…

TreeFrog Therapeutics has raised $75 million in financing to support the clinical development of its stem cell-derived cell therapies for Parkinson’s disease, the company said in a press release. The new financing round, which brings the total funding to date to $83 million, will allow the company to use…

The Michael J. Fox Foundation (MJFF) has released a new suite of free educational resources that focuses on so-called “off” periods when Parkinson’s disease symptoms reappear or worsen as medications wear off. These new resources, available at michaeljfox.org/off, offer patients and their families tips for managing “off” time,…

The antioxidant urate failed to slow Parkinson’s disease progression in newly diagnosed patients over two years, according to data from a Phase 3 clinical trial. “While our study did not rule out a protective effect of urate in Parkinson’s, it clearly showed that increasing urate did not slow disease…

High prices, lack of access, and long waiting times are major barriers to people who want to undergo genetic testing for Parkinson’s disease, according to a survey by the International Parkinson and Movement Disorder Society (MDS). Survey results will be presented at the MDS Virtual Congress 2021, held…